Description
A prodrug form of azilsartan; reduces blood pressure and decreases PAI-1 levels in the plasma, left ventricle, and aortic wall in mice in a dose-dependent manner when administered at doses ranging from 0.1-10 mg/kg; inhibits the angiotensin II-induced pressor response in normotensive rats (ID50 = 0.12 mg/kg); reduces blood pressure and improves glucose infusion in spontaneously hypertensive rats; has more potent antiproteinuric effects in Wistar fatty rats than olmesartan medoxomil
Formal name: 1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1′-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
Synonyms: TAK-491
Molecular weight: 568.5
CAS: 863031-21-4
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Blood|Serum Proteins||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Kidney & Renal Disease||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes